Oxilorphan

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Oxilorphan
Oxilorphan.svg
Systematic (IUPAC) name
(-)-17-(Cyclopropylmethyl)-morphinan-3,14-diol
Clinical data
Legal status ?
Identifiers
CAS number 42281-59-4 YesY
ATC code None
PubChem CID 5361090
ChemSpider 16736680 YesY
UNII 9Y9J2J74TO YesY
KEGG D05299 YesY
Chemical data
Formula C20H27NO2 
Mol. mass 313.44 g/mol
 YesY (what is this?)  (verify)

Oxilorphan is an opioid antagonist from the morphinan family of drugs.

Oxilorphan is a non-selective opioid which is a μ antagonist but a κ partial agonist. It has similar effects to naloxone, and around the same potency as an antagonist.[1]

Oxilorphan has some weak partial agonist effects[2] and can produce hallucinogenic/dissociative effects at high doses, suggesting some kappa opioid agonist action.[3] It was trialled for the treatment of opiate addiction, but was not developed commercially.[4] Oxilorphan's mu-opioid antagonist and kappa-opioid agonist effects are associated with dysphoria, which combined with the hallucinogenic properties of kappa-opioid agonism limit the clinical usefulness of the drug.

See also[edit]

References[edit]

  1. ^ Pircio AW, Gylys JA. Oxilorphan (l-N-cyclopropylmethyl-3,14-dihydroxymorphinan): a new synthetic narcotic antagonist. Journal of Pharmacology and Experimental Therapeutics. 1975 Apr;193(1):23-34.
  2. ^ Sellers EM, Thakur R. Partial agonist properties and toxicity of oral oxilorphan. Journal of Clinical Pharmacology. 1976 Apr;16(4):183-7.
  3. ^ Leander JD. Evidence that nalorphine, butorphanol and oxilorphan are partial agonists at a kappa-opioid receptor. European Journal of Pharmacology. 1983 Jan 21;86(3-4):467-70.
  4. ^ Tennant FS Jr, Tate JA, Ruckel E. Clinical trial in post-addicts with oxilorphan (levo-BC-2605): a new narcotic antagonist. Drug and Alcohol Dependence. 1976 Jun;1(5):329-37.